JMP reiterates Market Outperform rating on GH Research stock at $39 target

Published 24/07/2025, 10:26
JMP reiterates Market Outperform rating on GH Research stock at $39 target

Investing.com - JMP Securities has reiterated its Market Outperform rating and $39 price target on GH Research PLC (NASDAQ:GHRS), currently trading at $14.24, citing progress in FDA discussions and strong clinical data. The company, valued at $883 million, maintains strong analyst support with a consensus "Buy" rating and price targets ranging from $25 to $40.

The company announced Thursday that it has received feedback from the FDA regarding its submission to address a clinical hold for its GH001 drug candidate. According to the announcement, only one issue remains open with regulators - the relevance of respiratory tract histology findings in rats - while all other items for the hold have been resolved.

JMP analyst Jason Butler expressed confidence that the rat findings are species-specific and not relevant to human applications. The firm maintains its $39 risk-adjusted, DCF-derived price target, highlighting the "blockbuster potential" of GH001.

GH Research also disclosed final results from the open-label extension portion of its Phase 2b trial in treatment-resistant depression on Thursday. The company reported that remission rates were consistent with interim results previously announced in February.

The firm’s analysis focuses on GH Research’s ongoing FDA engagement, with JMP citing the strong Phase 2b and open-label extension data as key factors supporting its positive outlook on the stock.

In other recent news, GH Research PLC has been actively engaging with the U.S. Food and Drug Administration regarding a clinical hold on its Investigational New Drug Application for GH001. The company has submitted a complete response addressing the FDA’s requests, with a focus on resolving an issue related to respiratory tract histology findings in rats. GH Research believes these findings are specific to rats, based on scientific evidence. Canaccord Genuity analyst Sumant Kilkami reiterated a Buy rating for the company, maintaining a price target of $35.00. Meanwhile, Cantor Fitzgerald analysts have assumed coverage of GH Research with an Overweight rating and set a price target at $25.00, citing the potential impact of psychedelics on mental health disorders. The analysts emphasize the significant unmet need for effective treatments in areas such as depression, PTSD, and anxiety. GH Research’s ongoing dialogue with the FDA and analyst support highlight the company’s potential in the mental health sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.